Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform

Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that Innovate GBM, a 501(c)(3) nonprofit organization dedicated to accelerating the development of new treatments for glioblastoma (GBM) and other brain tumors, has engaged two ai² PIPELINE project teams to…